Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSZQAK)

• Drug Name: Amphetamine Drug Info
• Synonyms: Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Approved	[1]
Depression	6A70-6A7Z	Approved	[2]
Narcolepsy	7A20	Approved	[2]
Obesity	5B81	Approved	[2]

• Cross-matching ID:
  PubChem CID: 3007
  ChEBI ID: CHEMBL405
  CAS Number: CAS 300-62-9
  TTD Drug ID: DMSZQAK
  VARIDT Drug ID: DR00084
  INTEDE Drug ID: DR0106
  ACDINA Drug ID: D00036

Molecule-Related Drug Atlas

Drug(s) Targeting Trace amine-associated receptor-1 (TAAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lisdexamfetamine	DM6W8V5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[16]
Dextroamphetamine	DMMIHVP	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Hydroxyamphetamine Hydrobromide	DMQSGM0	Horner syndrome	8D8A.1	Approved	[17]
SEP-363856	DMG2QP4	Schizophrenia	6A20	Phase 3	[18]
NT0202	DMCMIJ1	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[3]
SPD-465	DM7NV1I	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[3]
RG-7351	DMFGR98	Major depressive disorder	6A70.3	Phase 1	[19]
tyramine	DM4UXT1	Discovery agent	N.A.	Investigative	[20]
EPPTB	DMK3VID	Discovery agent	N.A.	Investigative	[21]
R(-)amphetamine	DM72ES1	Discovery agent	N.A.	Investigative	[22]

Drug(s) Transported By Organic cation transporter 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[23]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[24]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[25]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[23]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[26]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[24]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[24]
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[27]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[28]
Etilefrine	DM67PWD	Cardiovascular disease	BA00-BE2Z	Withdrawn from market	[29]

Drug(s) Transported By Organic cation/carnitine transporter 2 (SLC22A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[30]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[31]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[26]
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[32]
Potassium Chloride	DMMTAJC	Hypokalemia	5C77	Approved	[33]
Tiotropium	DMFDC0Q	Chronic obstructive pulmonary disease	CA22	Approved	[34]
Ipratropium	DMFQ320	Obstructive lung disease	CA22.Z	Approved	[34]
Mepyramine	DMB4SFH	Allergic rhinitis	CA08.0	Approved	[35]
Acetylcarnitine	DM4UE3K	Chronic fatigue syndrome	8E49	Phase 4	[36]
acetyl-L-carnitine	DM74HGJ	Discovery agent	N.A.	Investigative	[31]

Drug(s) Transported By Sodium-dependent noradrenaline transporter (SLC6A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[37]

Drug(s) Transported By Sodium-dependent dopamine transporter (SLC6A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[38]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[39]
Bretylium	DM1FX74	Long QT syndrome	BC65.0	Approved	[40]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[41]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[52]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[53]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[54]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[55]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[55]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Dextroamphetamine	DMMIHVP	Attention deficit hyperactivity disorder	6A05.Z	Approved	[57]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[58]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[59]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[60]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[43]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[46]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[47]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[48]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[49]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[50]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[51]

Drug(s) Affected By Protein c-Fos (FOS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[62]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[63]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[64]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[63]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[69]

Drug(s) Affected By Proenkephalin-A (PENK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[70]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[71]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[14]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[58]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[60]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[72]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[73]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[74]

Drug(s) Affected By Transcription factor Jun (JUN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[75]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[76]
Fructose	DM43AN2	Vomiting	MD90	Approved	[77]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[78]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[79]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[64]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[81]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[82]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[83]

Drug(s) Affected By Glial fibrillary acidic protein (GFAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penicillin V	DMKVOYF	Acute otitis media	AB00	Approved	[77]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[77]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[84]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[85]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[86]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[87]
Haloperidol	DM96SE0	Delirium		Approved	[88]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[89]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[90]

Drug(s) Affected By Transcription factor JunB (JUNB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[79]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[91]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[92]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[93]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[94]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[96]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[97]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[98]

Drug(s) Affected By Transcription factor JunD (JUND)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[79]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[64]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[99]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[93]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[101]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[102]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[103]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[104]

Drug(s) Affected By Protein FosB (FOSB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[105]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[92]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[106]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[107]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[108]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[109]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[96]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[110]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[111]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[112]

Drug(s) Affected By Fatty-acid amide hydrolase 1 (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[113]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[115]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[116]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[117]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[118]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[119]
ASP-8477	DMBZQS7	Neuropathic pain	8E43.0	Phase 2	[120]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[121]

Drug(s) Affected By D(2) dopamine receptor (DRD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Droperidol	DM0DXA8	Nausea	MD90	Approved	[77]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[77]
Zuclopenthixol	DMKYD5N	Schizophrenia	6A20	Approved	[77]
Meglitinides	DM1OFHN	Type-2 diabetes	5A11	Approved	[122]
Sulpiride	DMF54ZG	Schizophrenia	6A20	Approved	[123]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[124]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[125]
Methamphetamine	DMPM4SK	Anxiety		Approved	[126]
Bromocriptine	DMVE3TK	Acromegaly	5A60.0	Approved	[127]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[128]

Drug(s) Affected By Casein kinase I isoform epsilon (CSNK1E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[129]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[130]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[131]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[132]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[133]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[134]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[58]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[135]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[136]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[137]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[138]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[139]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[140]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[141]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[142]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[141]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[137]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[77]

Drug(s) Affected By Adenosine receptor A2a (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[143]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[93]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[144]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[145]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[146]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[147]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[144]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[144]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Trace amine-associated receptor-1 (TAAR1)	TTIU98M	TAAR1_HUMAN	Modulator	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-dependent dopamine transporter (SLC6A3)	DT3BA8L	SC6A3_HUMAN	Substrate	[4]
Sodium-dependent noradrenaline transporter (SLC6A2)	DT9JBVI	SC6A2_HUMAN	Substrate	[4]
Organic cation/carnitine transporter 2 (SLC22A5)	DT3HUVD	S22A5_HUMAN	Substrate	[5]
Organic cation transporter 3 (SLC22A3)	DT6201N	S22A3_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[7]
Tyramine oxidase (tynA)	DEB3TNR	AMO_ECOLI	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Adenosine receptor A2a (ADORA2A)	OTVRBZ0I	AA2AR_HUMAN	Drug Response	[9]
Casein kinase I isoform epsilon (CSNK1E)	OTF0UXX6	KC1E_HUMAN	Drug Response	[10]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Biotransformations	[11]
D(2) dopamine receptor (DRD2)	OTBLXKEG	DRD2_HUMAN	Drug Response	[12]
Fatty-acid amide hydrolase 1 (FAAH)	OT9DX3N1	FAAH1_HUMAN	Drug Response	[13]
Glial fibrillary acidic protein (GFAP)	OTQ01ZAS	GFAP_HUMAN	Gene/Protein Processing	[14]
Proenkephalin-A (PENK)	OT8P3HMP	PENK_HUMAN	Gene/Protein Processing	[14]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Gene/Protein Processing	[14]
Protein FosB (FOSB)	OTW6C05J	FOSB_HUMAN	Gene/Protein Processing	[14]
Sodium-dependent dopamine transporter (SLC6A3)	OT39XG28	SC6A3_HUMAN	Drug Response	[15]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Amphetamine FDA Label
• [3] Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
• [4] Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
• [5] Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
• [6] Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
• [7] Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
• [8] Mechanistic elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota using molecular dynamics simulations. J Cell Biochem. 2019 Jan 30.
• [9] Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 5;139B(1):42-4. doi: 10.1002/ajmg.b.30228.
• [10] Association between the casein kinase 1 epsilon gene region and subjective response to D-amphetamine. Neuropsychopharmacology. 2006 May;31(5):1056-63. doi: 10.1038/sj.npp.1300936.
• [11] Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett. 2018 Mar 15;285:1-8. doi: 10.1016/j.toxlet.2017.12.017. Epub 2017 Dec 23.
• [12] Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. Exp Clin Psychopharmacol. 2009 Dec;17(6):374-83. doi: 10.1037/a0017840.
• [13] More aroused, less fatigued: fatty acid amide hydrolase gene polymorphisms influence acute response to amphetamine. Neuropsychopharmacology. 2010 Feb;35(3):613-22. doi: 10.1038/npp.2009.166. Epub 2009 Nov 4.
• [14] Effect of acute and chronic psychostimulant drugs on redox status, AP-1 activation and pro-enkephalin mRNA in the human astrocyte-like U373 MG cells. Neuropharmacology. 2005 Apr;48(5):673-84. doi: 10.1016/j.neuropharm.2004.12.010.
• [15] Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005 Mar;30(3):602-9. doi: 10.1038/sj.npp.1300637.
• [16] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [17] Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Clinical pipeline report, company report or official report of Roche.
• [20] Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One. 2011;6(10):e27073.
• [21] The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6.
• [22] The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39.
• [23] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [24] Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
• [25] Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
• [26] Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
• [27] Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
• [28] Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
• [29] Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
• [30] Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
• [31] Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
• [32] Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
• [33] Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
• [34] Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
• [35] Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
• [36] Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
• [37] Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51.
• [38] Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
• [39] Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 Mar;234(6):1017-1028.
• [40] Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J Biol Chem. 1999 Feb 19;274(8):4876-82.
• [41] Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist. J Pharmacol Exp Ther. 2014 Jan;348(1):106-15.
• [42] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [43] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [44] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [45] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [46] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [47] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [48] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [49] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [50] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [51] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [52] Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca(2+) channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513. doi: 10.1016/j.taap.2021.115513. Epub 2021 Mar 27.
• [53] Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. J Biol Chem. 2016 Oct 14;291(42):22053-22062. doi: 10.1074/jbc.M116.749119. Epub 2016 Aug 23.
• [54] Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in?vivo assays in mice. Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.
• [55] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [56] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [57] Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR. Neurotoxicology. 2019 May;72:95-100. doi: 10.1016/j.neuro.2019.02.011. Epub 2019 Feb 15.
• [58] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [59] Pyrethroid pesticide-induced alterations in dopamine transporter function. Toxicol Appl Pharmacol. 2006 Mar 15;211(3):188-97. doi: 10.1016/j.taap.2005.06.003. Epub 2005 Jul 11.
• [60] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [61] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [62] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [63] Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
• [64] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [65] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [66] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [67] Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
• [68] Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
• [69] The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
• [70] The role of acetaldehyde in mediating effects of alcohol on expression of endogenous opioid system genes in a neuroblastoma cell line. FASEB J. 2008 Mar;22(3):662-70. doi: 10.1096/fj.07-8346com. Epub 2007 Oct 12.
• [71] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [72] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [73] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [74] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [75] High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1993 Nov 15;82(10):3133-40.
• [76] Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
• [77] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [78] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [79] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [80] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [81] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [82] Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
• [83] [Regulation mechanism of autophagy-related protein LC3 by c-Jun in methotrexate resistant human choriocarcinoma JEG-3 cells]. Zhonghua Fu Chan Ke Za Zhi. 2014 Jul;49(7):531-5.
• [84] miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol. 2013 Aug;29(4):239-57. doi: 10.1007/s10565-013-9250-5. Epub 2013 Aug 1.
• [85] A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med. 2008 May;215(1):55-9. doi: 10.1620/tjem.215.55.
• [86] Aspirin-induced blockade of NF-kappaB activity restrains up-regulation of glial fibrillary acidic protein in human astroglial cells. Biochim Biophys Acta. 2006 Mar;1763(3):282-9. doi: 10.1016/j.bbamcr.2006.01.005. Epub 2006 Feb 21.
• [87] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [88] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [89] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [90] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [91] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [92] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [93] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [94] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [95] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [96] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [97] Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med (Maywood). 2013 Aug 1;238(8):932-42. doi: 10.1177/1535370213492689. Epub 2013 Jul 24.
• [98] DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
• [99] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [100] Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
• [101] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [102] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [103] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [104] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [105] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [106] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [107] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [108] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [109] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [110] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [111] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [112] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [113] Cannabidiol regulates CB1-pSTAT3 signaling for neurite outgrowth, prolongs lifespan, and improves health span in Caenorhabditis elegans of A pathology models. FASEB J. 2021 May;35(5):e21537. doi: 10.1096/fj.202002724R.
• [114] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [115] Effects of cannabis tetrahydrocannabinol on endocannabinoid homeostasis in human placenta. Arch Toxicol. 2019 Mar;93(3):649-658. doi: 10.1007/s00204-019-02389-7. Epub 2019 Jan 18.
• [116] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [117] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [118] Further insights into the regulation of human FAAH by progesterone and leptin implications for endogenous levels of anandamide and apoptosis of immune and neuronal cells. Neurotoxicology. 2005 Oct;26(5):811-7.
• [119] Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics. 2004 Jan 15;16(2):204-11.
• [120] In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor. Eur J Pharmacol. 2017 Nov 15;815:42-48. doi: 10.1016/j.ejphar.2017.10.007. Epub 2017 Oct 7.
• [121] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [122] Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008 Apr;197(2):229-35. doi: 10.1007/s00213-007-1029-z. Epub 2007 Dec 6.
• [123] Positron emission tomography measurement of dopamine D? receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010 Sep;71(9):1131-7. doi: 10.4088/JCP.08m04307yel. Epub 2010 Feb 23.
• [124] Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May;19(5):373-82. doi: 10.1097/FPC.0b013e328329a60f.
• [125] Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010 Jun;20(6):359-66. doi: 10.1097/FPC.0b013e3283397d06.
• [126] A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr Psychiatry. 2008 Jul-Aug;49(4):387-92. doi: 10.1016/j.comppsych.2008.01.008. Epub 2008 Mar 21.
• [127] Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006 Sep 25;405(3):196-201. doi: 10.1016/j.neulet.2006.07.030. Epub 2006 Aug 8.
• [128] Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. doi: 10.1073/pnas.0609752104. Epub 2007 Jul 2.
• [129] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [130] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [131] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [132] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [133] Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006 Apr 3;7:68. doi: 10.1186/1471-2164-7-68.
• [134] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [135] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [136] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [137] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [138] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [139] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [140] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [141] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [142] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [143] Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther. 2012 Jun 8;14(3):R138. doi: 10.1186/ar3871.
• [144] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [145] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [146] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [147] New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signal. 2007 Sep;3(4):339-46. doi: 10.1007/s11302-007-9068-9. Epub 2007 Sep 19.